A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Trial Profile

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-042
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 28 Feb 2018 to 31 Jan 2020.
    • 09 Apr 2018 According to a Merck AG media release, results from this trial will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
    • 09 Apr 2018 Results published in the Merck AG Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top